A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes

NCT01951235 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

315

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Imeglimin
DRUG: Placebo

Sponsor

Poxel SA